Teva announces recruitment completion of Phase III clinical Study of mdc-TJK/Olanzapine LAI

Published: 10-Jan-2024
Research & Development

Teva Pharmaceutical Industries announced the successful completion of the enrollment in the EU and US of the anticipated 640 participants of the ongoing Phase III clinical trial of mdc-TJK (TEV-44749) at the J.P. Morgan Healthcare Conference

Results of the study are expected in the second half of 2024. mdc-TJK is an investigational once-monthly subcutaneous long-acting injection of the atypical antipsychotic olanzapine for the
treatment of schizophrenia.

It has the potential to be the first long-acting olanzapine with a favorable safety profile. Teva remains fully responsible to lead the development and commercialisation of olanzapine LAI globally.

MedinCell may receive up to $117m in development and commercial milestones during the coming years for mdc-TJK, and is eligible for royalties on all net sales.

  • Companies:
  • Teva
  • MedinCell
See more

You may also like

Research & Development

Teva UK and Closed Loop Medicine partner to advance personalised medicine development

Read more
SaMD platform aims to advance personalised medicine development, improve drug efficacy and patient outcomes with specific chronic conditions

Trending Articles

  1. Memel Biotech and Therabest collaborate to develop exosome-based cell therapies The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
  2. Owlstone Medical bags $6.5m to optimise infectious disease diagnostic tool The Bill & Melinda Gates Foundation has funded the bolstering of the Breath Biopsy platform, as well as research into breath biomarkers in tuberculosis (TB) and HIV
  3. Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
  4. Amarna Therapeutics appoints Aurelia Caparrós as new Chief Business Officer Aurellia will be reponsible for driving Amarna's growth in the Netherlands and Spain
  5. Macomics unveils Anti-Pan-LILRB monoclonal antibody programme Data presented at AACR 2024 shows MACO-355 is highly potent in macrophage reprogramming under tumour-like immune suppressed conditions

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Research & Development

Teva UK and Closed Loop Medicine partner to advance personalised medicine development

SaMD platform aims to advance personalised medicine development, improve drug efficacy and patient outcomes with specific chronic conditions
Research & Development

Sanofi and Teva's collaboration to deliver inflammatory bowel disease treatment

TEV’574, a novel anti-TL1A therapy, is being developed to treat ulcerative colitis and Crohn’s disease by Sanofi and Teva Pharmaceuticals
Research & Development

Teva completes facilities purchase in Pennsylvania

Investment will see the Israeli drug-maker set up a Research & Development campus in the US
Research & Development

Teva buys rights to develop small-molecule CGRP antagonists

Enters into agreement with Heptares to develop novel products for the treatment of migraine
Regulatory

Asthma – reslizumab

Acute asthma attacks can require hospitalisation or even prove fatal, but in some sufferers the standard regimen does not give adequate control
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

New NCEs focus on cancer and orphan diseases

The number of NCEs approved in Europe increased again in 2014, with the spotlight on cancer drugs and treatments for unmet medical needs. Dr Sarah Houlton reviews the new entrants
Research & Development

Teva to cancel or sell off 14 pipeline projects

Will redirect US$550m in funds from these projects to core areas of CNS and respiratory
Subscribe now